Skip to main content
Clinical Trials/NCT04525261
NCT04525261
Completed
Not Applicable

Natural History of Patients With Inherited Retinal Diseases Due to Mutations in RPE65 Gene

University of Campania "Luigi Vanvitelli"9 sites in 1 country60 target enrollmentMay 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Leber Congenital Amaurosis 2
Sponsor
University of Campania "Luigi Vanvitelli"
Enrollment
60
Locations
9
Primary Endpoint
visual field
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Rationale:

In preparation for treatment with gene therapy, this study is being conducted in order to investigate the natural history of Inherited Retinal Dystrophies (IRDs) due to mutations in RPE65 gene. Such a study will help identify suitable patients for therapeutic intervention.

Methodology:

This is a multicenter retrospective, descriptive chart review study designed to assess retinal structure and function in subjects with IRDs due to mutation in RPE65 gene by visual acuity, visual field measurements, Optical Coherence Tomography (OCT), and a number of other vision-related assessments.

Registry
clinicaltrials.gov
Start Date
May 1, 2020
End Date
July 31, 2020
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Francesca Simonelli

Prof

University of Campania "Luigi Vanvitelli"

Eligibility Criteria

Inclusion Criteria

  • Must be willing to adhere to protocol as evidenced by written informed consent or parental permission and subject assent.
  • Subjects diagnosed with Retinitis Pigmentosa or Leber Congenital Amaurosis.
  • Molecular diagnosis showing mutations (homozygotes or compound heterozygotes) in RPE65 gene.
  • Age three years old or older.
  • Minimum of two office / clinic visits encounters with ophthalmic assessment that span a follow-up period of at least 1 year with the last visit occurring within the last six months (before signature of informed consent and of study start).

Exclusion Criteria

  • Unable or unwilling to meet requirements of the study.
  • Participation in a clinical study with an investigational drug during the retrospective study time period (i.e., from 01/01/1990 to study start date).

Outcomes

Primary Outcomes

visual field

Time Frame: at least one year

average annual progression rate of visual field over the retrospective follow-up period

best correct visual acuity

Time Frame: at least one year

average annual progression rate of best correct visual acuity over the retrospective follow-up period

optical coherence tomography

Time Frame: at least one year

average annual progression rate of central retinal thickness over the retrospective follow-up period

Secondary Outcomes

  • Multifocal Electroretinogram(at least one year)
  • fundus autofluorescence(at least one year)
  • microperimetry(at least one year)
  • Full-field Electroretinogram(at least one year)

Study Sites (9)

Loading locations...

Similar Trials